SG11201608441YA - Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect - Google Patents

Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect

Info

Publication number
SG11201608441YA
SG11201608441YA SG11201608441YA SG11201608441YA SG11201608441YA SG 11201608441Y A SG11201608441Y A SG 11201608441YA SG 11201608441Y A SG11201608441Y A SG 11201608441YA SG 11201608441Y A SG11201608441Y A SG 11201608441YA SG 11201608441Y A SG11201608441Y A SG 11201608441YA
Authority
SG
Singapore
Prior art keywords
prevention
salt
treatment
pharmaceutical composition
composition containing
Prior art date
Application number
SG11201608441YA
Other languages
English (en)
Inventor
Takashi Mizutani
Chihoko Yoshimura
Hitomi Kondo
Makoto Kitade
Shuichi Ohkubo
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of SG11201608441YA publication Critical patent/SG11201608441YA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SG11201608441YA 2014-06-24 2015-06-24 Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect SG11201608441YA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2014129740 2014-06-24
JP2015024785 2015-02-10
PCT/JP2015/068218 WO2015199136A1 (ja) 2014-06-24 2015-06-24 新規ピロロピリミジン化合物又はその塩、及びこれを含有する医薬組成物、特にnae阻害作用に基づく腫瘍等の予防剤及び/又は治療剤

Publications (1)

Publication Number Publication Date
SG11201608441YA true SG11201608441YA (en) 2016-11-29

Family

ID=54938214

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201608441YA SG11201608441YA (en) 2014-06-24 2015-06-24 Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect

Country Status (21)

Country Link
US (2) US9963456B2 (ja)
EP (1) EP3103802B1 (ja)
JP (1) JP6192741B2 (ja)
KR (1) KR101947289B1 (ja)
CN (1) CN106661031B (ja)
AU (1) AU2015281155B9 (ja)
BR (1) BR112016025835B1 (ja)
CA (1) CA2946833C (ja)
DK (1) DK3103802T3 (ja)
ES (1) ES2656772T3 (ja)
HU (1) HUE037266T2 (ja)
MX (1) MX2016015015A (ja)
MY (1) MY183327A (ja)
NO (1) NO3103802T3 (ja)
PH (1) PH12016502130A1 (ja)
PL (1) PL3103802T3 (ja)
PT (1) PT3103802T (ja)
RU (1) RU2658008C2 (ja)
SG (1) SG11201608441YA (ja)
TW (1) TWI605048B (ja)
WO (1) WO2015199136A1 (ja)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI623316B (zh) * 2015-12-22 2018-05-11 Taiho Pharmaceutical Co Ltd Antitumor effect enhancer derived from pyrrolopyrimidine compound
WO2018085833A2 (en) * 2016-11-07 2018-05-11 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyl transferase 5 (prmt5)
WO2018085818A1 (en) * 2016-11-07 2018-05-11 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
WO2018089786A1 (en) * 2016-11-11 2018-05-17 Millennium Pharmaceuticals, Inc. Atg7 inhibitors and the uses thereof
JP7125714B2 (ja) * 2016-12-13 2022-08-25 ヤマサ醤油株式会社 抗ウイルス活性を有する2’-デオキシ-7-デアザプリンヌクレオシド誘導体
CN111971286B (zh) * 2018-01-18 2023-04-14 阿雷生物药品公司 作为RET激酶抑制剂的取代的吡咯并[2,3-d]嘧啶化合物
CN108822145B (zh) * 2018-06-11 2020-10-23 广东工业大学 一种磺酰胺类化合物及其制备方法和应用
CN108640945B (zh) * 2018-06-11 2020-10-23 广东工业大学 一种酰胺类化合物及其制备方法与应用
EP3820533A2 (en) * 2018-07-13 2021-05-19 IL-2RX, Inc. Compounds, compositions, methods, and uses for treating cancer and immunological disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1848718T3 (da) 2005-02-04 2012-08-27 Millennium Pharm Inc E1 aktiveringsenzymhæmmere
US7989430B2 (en) 2005-12-06 2011-08-02 Regents Of The University Of Minnesota Antibacterial agents
EA031335B1 (ru) 2006-02-02 2018-12-28 Миллениум Фармасьютикалз, Инк. Производные пирролопиримидинов
JP2013541587A (ja) * 2010-11-05 2013-11-14 ミレニアム ファーマシューティカルズ, インコーポレイテッド Nedd8活性化酵素阻害剤の投与
EP2661436B1 (en) 2011-01-07 2016-04-13 Leo Pharma A/S Novel sulfamide piperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof
EP2738873A4 (en) * 2011-07-29 2015-04-01 Kuang Chi Innovative Tech Ltd ARTIFICIAL COMPOSITE MATERIAL AND ANTENNA CONSISTING OF ARTIFICIAL COMPOSITE MATERIAL
AU2013210403B2 (en) * 2012-01-19 2016-01-14 Taiho Pharmaceutical Co., Ltd. 3,5-disubstituted alkynylbenzene compound and salt thereof

Also Published As

Publication number Publication date
TWI605048B (zh) 2017-11-11
HUE037266T2 (hu) 2018-08-28
US20170066772A1 (en) 2017-03-09
EP3103802A1 (en) 2016-12-14
PH12016502130B1 (en) 2016-12-19
CN106661031B (zh) 2019-07-23
US9963456B2 (en) 2018-05-08
CN106661031A (zh) 2017-05-10
AU2015281155B9 (en) 2017-11-16
EP3103802A4 (en) 2017-03-08
JP6192741B2 (ja) 2017-09-06
DK3103802T3 (en) 2017-12-11
RU2016149319A (ru) 2018-06-18
BR112016025835A2 (ja) 2017-08-15
KR20170016510A (ko) 2017-02-13
AU2015281155B2 (en) 2017-07-13
PH12016502130A1 (en) 2016-12-19
PT3103802T (pt) 2017-12-11
AU2015281155A1 (en) 2016-11-03
MY183327A (en) 2021-02-18
KR101947289B1 (ko) 2019-02-12
PL3103802T3 (pl) 2018-02-28
US10174040B2 (en) 2019-01-08
NO3103802T3 (ja) 2018-04-07
JPWO2015199136A1 (ja) 2017-04-27
CA2946833A1 (en) 2015-12-30
ES2656772T3 (es) 2018-02-28
US20180162864A1 (en) 2018-06-14
RU2016149319A3 (ja) 2018-06-18
TW201625629A (zh) 2016-07-16
BR112016025835B1 (pt) 2022-09-20
EP3103802B1 (en) 2017-11-08
CA2946833C (en) 2019-03-05
WO2015199136A1 (ja) 2015-12-30
MX2016015015A (es) 2017-02-27
RU2658008C2 (ru) 2018-06-19

Similar Documents

Publication Publication Date Title
IL264049A (en) Compounds, preparations and methods for treating the disease
HK1247922A1 (zh) 用於治療癌症的吲哚胺2,3-雙加氧酶抑制劑
IL264156A (en) Compounds, preparations and methods for treating the disease
SG11201608441YA (en) Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect
EP3390357A4 (en) BIARYLMONOBACTAM COMPOUNDS AND CORRESPONDING METHODS OF USE FOR THE TREATMENT OF BACTERIAL INFECTIONS
PL3065732T3 (pl) Związki, kompozycje i odpowiednie zastosowania do zapobiegania i/lub leczenia dyslipidemii
IL263697A (en) Compounds, preparations and methods for the treatment and/or prevention of cancer
EP3231436A4 (en) Pharmaceutical composition for prevention or treatment of metabolic disease, comprising bacteroides acidifaciens as effective ingredient
ZA201707951B (en) Amide compound and use thereof as agent for the treatment and prevention of diseases caused by rna- and/or dna-containing viruses, and concomitant diseases
IL263793A (en) Compounds and preparations for the treatment of cancer
EP3241551A4 (en) Pharmaceutical composition for treating cancer, containing lactate metal salt
IL275525A (en) A pharmaceutical preparation for the treatment of cancer
HK1232128A1 (zh) 用於預防或治療皮疹的藥物組合物
EP3162803A4 (en) New compound for inhibiting binding between dx2 protein and p14/arf protein, and pharmaceutical composition for treating or preventing cancer disease containing same as effective ingredient
EP3290051A4 (en) Pharmaceutical composition for treating and/or preventing cancer
HK1249044A1 (zh) 用於治療或預防神經退行性疾病的槍刀藥素氧化物、其衍生物、相關化合物和激動劑
EP3235808A4 (en) Modified taurine, and pharmaceutical composition for preventing or treating metabolic diseases containing same
EP3677267A4 (en) PHARMACEUTICAL COMPOSITION FOR TREATMENT OR PREVENTION OF TUMORS, METHOD AND USES THEREOF
IL252487A0 (en) Arylalkylamine compounds for use in the prevention or treatment of cancer
EP3372233A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER
HUE051563T2 (hu) Gyógyszerkészítmény rák megelõzésére vagy kezelésére
EP3556363A4 (en) USE OF A CARBAMATE COMPOUND FOR PREVENTING, RELIEVING OR TREATING PRURITUS
EP3388067A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF CANCER
EP3326631A4 (en) PAC-1 COMPOUND OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME